USP8 is a Novel Therapeutic Target in Melanoma Through Regulating Receptor Tyrosine Kinase Levels

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.2125425559415
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted therapy in melanoma and mechanisms of resistance. Int J Mol Sci. 2020;21(13):4576. doi:10.3390/ijms21134576
   PubMed Web of Science ®Google Scholar
• Antao AM, Tyagi A, Kim KS, Ramakrishna S. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers. 2020;12(6):1579. doi:10.3390/cancers12061579
   PubMed Web of Science ®Google Scholar
• Young MJ, Hsu KC, Lin TE, Chang WC, Hung JJ. The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci. 2019;26(1):42. doi:10.1186/s12929-019-0522-031133011
   PubMed Web of Science ®Google Scholar
• Love KR, Catic A, Schlieker C, Ploegh HL. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol. 2007;3(11):697–705. doi:10.1038/nchembio.2007.4317948018
   PubMed Web of Science ®Google Scholar
• Jing X, Chen Y, Chen Y, et al. Down-regulation of USP8 inhibits cholangiocarcinoma cell proliferation and invasion. Cancer Manag Res. 2020;12:2185–2194. doi:10.2147/CMAR.S23458632273758
   PubMed Web of Science ®Google Scholar
• Yan M, Zhao C, Wei N, Wu X, Cui J, Xing Y. High expression of ubiquitin-specific protease 8 (USP8) is associated with poor prognosis in patients with cervical squamous cell carcinoma. Med Sci Mon. 2018;24:4934–4943. doi:10.12659/MSM.909235
   PubMed Web of Science ®Google Scholar
• Byun S, Lee SY, Lee J, et al. USP8 is a novel target for overcoming gefitinib resistance in lung cancer. Clin Cancer Res. 2013;19(14):3894–3904. doi:10.1158/1078-0432.CCR-12-369623748694
   PubMed Web of Science ®Google Scholar
• Baykara M, Yaman M, Buyukberber S, et al. Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer. J BUON. 2013;18(4):921–927.24344018
   PubMed Web of Science ®Google Scholar
• Niendorf S, Oksche A, Kisser A, et al. Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Mol Cell Biol. 2007;27(13):5029–5039. doi:10.1128/MCB.01566-0617452457
   PubMed Web of Science ®Google Scholar
• Jeong CH. Inhibition of ubiquitin-specific peptidase 8 suppresses growth of gefitinib-resistant non-small cell lung cancer cells by inducing apoptosis. J Cancer Prev. 2015;20(1):57–63. doi:10.15430/JCP.2015.20.1.5725853104
   PubMedGoogle Scholar
• Jian FF, Li YF, Chen YF, et al. Inhibition of ubiquitin-specific peptidase 8 suppresses adrenocorticotropic hormone production and tumorous corticotroph cell growth in AtT20 cells. Chin Med J. 2016;129(17):2102–2108. doi:10.4103/0366-6999.18904727569239
   PubMed Web of Science ®Google Scholar
• Easty DJ, Gray SG, O’Byrne KJ, O’Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res. 2011;24(3):446–461. doi:10.1111/j.1755-148X.2011.00836.x21320293
   PubMed Web of Science ®Google Scholar
• Yang X, Peng X, Huang J. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation. Clin Transl Oncol. 2018;20(9):1145–1152. doi:10.1007/s12094-018-1833-429340974
   PubMed Web of Science ®Google Scholar
• Vincent KM, Postovit LM. Investigating the utility of human melanoma cell lines as tumour models. Oncotarget. 2017;8(6):10498–10509. doi:10.18632/oncotarget.1444328060736
   PubMedGoogle Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000;19(1):21–34.10840932
   PubMed Web of Science ®Google Scholar
• Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873–886. doi:10.1038/nrd384723060265
   PubMed Web of Science ®Google Scholar
• Pham DDM, Guhan S, Tsao H. KIT and melanoma: biological insights and clinical implications. Yonsei Med J. 2020;61(7):562–571. doi:10.3349/ymj.2020.61.7.56232608199
   PubMed Web of Science ®Google Scholar
• Gardner FP, Serie DJ, Salomao DR, et al. c-MET expression in primary and liver metastases in uveal melanoma. Melanoma Res. 2014;24(6):617–620. doi:10.1097/CMR.000000000000011825211165
   PubMed Web of Science ®Google Scholar
• Tanguturi P, Kim KS, Ramakrishna S. The role of deubiquitinating enzymes in cancer drug resistance. Cancer Chemother Pharmacol. 2020;85(4):627–639. doi:10.1007/s00280-020-04046-832146496
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang J, Liang L, et al. Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin. J Cell Mol Med. 2020;24(7):4324–4340. doi:10.1111/jcmm.1509332129945
   PubMed Web of Science ®Google Scholar
• Vishnoi M, Boral D, Liu H, et al. Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs. Cancer Res. 2018;78(18):5349–5362. doi:10.1158/0008-5472.CAN-18-064430026332
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang B, Lei Y, et al. Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma. Tumour Biol. 2016;37(10):13167–13176. doi:10.1007/s13277-016-5212-x27456357
   PubMedGoogle Scholar
• Guo W, Ma J, Pei T, et al. Up-regulated deubiquitinase USP4 plays an oncogenic role in melanoma. J Cell Mol Med. 2018;22(5):2944–2954. doi:10.1111/jcmm.1360329542252
   PubMed Web of Science ®Google Scholar
• Kim Y, Shiba-Ishii A, Nakagawa T, et al. Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma. Pathol Int. 2017;67(6):292–301. doi:10.1111/pin.1254628544031
   PubMed Web of Science ®Google Scholar
• Colombo M, Vallese S, Peretto I, et al. Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem. 2010;5(4):552–558. doi:10.1002/cmdc.20090040920186914
   PubMed Web of Science ®Google Scholar